Is CD20 the only target radionuclide therapy in disorders?

被引：4

作者：

Agazzi, A

Rocca, P

Laszlo, D

Bodei, L

Grana, C

Martinelli, G

Paganelli, G

机构：

[1] European Inst Oncol, Hematooncol Div, I-20141 Milan, Italy

[2] European Inst Oncol, Div Nucl Med, Milan, Italy

来源：

EUROPEAN JOURNAL OF HAEMATOLOGY | 2005年 / 74卷 / 05期

关键词：

D O I：

10.1111/j.1600-0609.2005.00408.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：450 / 451

页数：2

共 4 条

[1]

Kwekkeboom D, 2000, J NUCL MED, V41, P1704

[2] Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide [J].

Paganelli, G ;

Zoboli, S ;

Cremonesi, M ;

Bodei, L ;

Ferrari, M ;

Grana, C ;

Bartolomei, M ;

Orsi, F ;

De Cicco, C ;

Mäacke, HR ;

Chinol, M ;

de Braud, F .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (04) :426-434

[3] INVITRO AND INVIVO DETECTION OF SOMATOSTATIN RECEPTORS IN HUMAN-MALIGNANT LYMPHOMAS [J].

REUBI, JC ;

WASER, B ;

VANHAGEN, M ;

LAMBERTS, SWJ ;

KRENNING, EP ;

GEBBERS, JO ;

LAISSUE, JA .

INTERNATIONAL JOURNAL OF CANCER, 1992, 50 (06) :895-900

[4]

Wiseman GA, 1999, CLIN CANCER RES, V5, p3281S

← 1 →